NEW YORK, March 13, 2018 – New research appears to confirm the association between fluoroquinolone antibiotics and acute aortic injuries.
The study, which was published this month in BMJ, drew data from Swedish health registries, with its authors identifying cases of aortic aneurysm or dissection that had occurred in the country from July 2006 to December 2013. A total of 360,000 cases in which the patients had been using fluoroquinolone antibiotics were compared to an equal number of cases where patients had been taking amoxicillin.
The analysis suggested that the use of Cipro, Avelox or Levaquin increased the risk for aortic injury by 66%, with 1.2 cases of aortic aneurysm or dissection occurring for every 1,000-person years in the fluoroquinolone group, compared to 0.7 cases among those taking amoxicillin. When the authors of the report looked at aortic aneurysm alone, the risk nearly doubled.
“Our firm is representing numerous individuals who were allegedly harmed by Levaquin, Cipro or Avelox, including several who suffered aortic aneurysm or aortic dissection. This study provides further evidence to support their claims,” says Sandy A. Liebhard LLP, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free, no-obligation legal reviews to individuals who were diagnosed with aortic injuries or peripheral neuropathy allegedly related to treatment with Levaquin, Cipro or Avelox.
Fluoroquinolone Side Effects
Levaquin, Cipro, and Avelox are used to treat a wide range of bacterial infections, including staph, pneumonia, urinary tract infections, E. coli and salmonella. While they are widely used, antibiotics in this class have been tied to a number of significant risks, including peripheral neuropathy and acute aortic injuries.
While the possibility of peripheral neuropathy was first noted on the drugs' labeling in 2004, the U.S. Food & Drug Administration (FDA) ordered fluoroquinolone manufacturers to updated their product labels in 2013 to better reflect the rapid onset of peripheral neuropathy symptoms, as well as the potential for permanent nerve damage
In May 2016, the FDA advised restricting the use of systemic fluoroquinolone antibiotics for certain uncomplicated infections, including acute sinusitis, acute bronchitis, and uncomplicated urinary tract infections, when other treatment options are available. The advisory was issued after an agency review concluded that fluoroquinolones were associated with severe and potentially permanent side effects involving the tendons, muscles, joints, nerves, and central nervous system.
Individuals who were diagnosed with peripheral neuropathy or aortic injuries following treatment with Levaquin, Cipro or Avelox may be entitled to compensation for their medical bills, lost wages and other damages related to their injuries. To learn more, please visit Bernstein Liebhard LLP's website. Free, no-obligation legal consultations can also be obtained by calling 800-511-5092.
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. Bernstein Liebhard LLP is honored to once again be named to The National Law Journal's “Plaintiffs' Hot List,” recognizing the top plaintiffs firms in the country. This year's nomination marks the thirteenth year the firm has been named to this prestigious annual list.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. Â© 2018 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
View original content with multimedia:http://www.prnewswire.com/news-releases/new-research-appears-to-confirm-increased-risk-of-aortic-aneurysm-aortic-dissection-from-levaquin-and-other-fluoroquinolone-antibiotics-bernstein-liebhard-llp-reports-300613282.html
SOURCE Bernstein Liebhard LLP
Latest posts by Jasmine Petters (see all)
- Second Annual Foodways Symposium Focuses on Native American Culture and Cooking - March 18, 2018
- First virtual reality interventional radiology training video unveiled at SIR 2018 - March 17, 2018
- Radius Health Presents Positive Data for the ACTIVExtend BMD Responder Analysis for TYMLOSâ„¢ (abaloparatide) Injection at ENDO 2018 Annual Meeting - March 17, 2018